Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Department of Statistics, Baylor University, Waco, Texas, USA.
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1219-1227. doi: 10.1002/pds.5117. Epub 2020 Sep 14.
We review statistical methods for assessing the possible impact of bias due to unmeasured confounding in real world data analysis and provide detailed recommendations for choosing among the methods.
By updating an earlier systematic review, we summarize modern statistical best practices for evaluating and correcting for potential bias due to unmeasured confounding in estimating causal treatment effect from non-interventional studies.
We suggest a hierarchical structure for assessing unmeasured confounding. First, for initial sensitivity analyses, we strongly recommend applying a recently developed method, the E-value, that is straightforward to apply and does not require prior knowledge or assumptions about the unmeasured confounder(s). When some such knowledge is available, the E-value could be supplemented by the rule-out or array method at this step. If these initial analyses suggest results may not be robust to unmeasured confounding, subsequent analyses could be conducted using more specialized statistical methods, which we categorize based on whether they require access to external data on the suspected unmeasured confounder(s), internal data, or no data. Other factors for choosing the subsequent sensitivity analysis methods are also introduced and discussed, including the types of unmeasured confounders and whether the subsequent sensitivity analysis is intended to provide a corrected causal treatment effect.
Various analytical methods have been proposed to address unmeasured confounding, but little research has discussed a structured approach to select appropriate methods in practice. In providing practical suggestions for choosing appropriate initial and, potentially, more specialized subsequent sensitivity analyses, we hope to facilitate the widespread reporting of such sensitivity analyses in non-interventional studies. The suggested approach also has the potential to inform pre-specification of sensitivity analyses before executing the analysis, and therefore increase the transparency and limit selective study reporting.
我们回顾了用于评估真实世界数据分析中未测量混杂偏倚可能影响的统计方法,并提供了选择这些方法的详细建议。
通过更新早期的系统综述,我们总结了现代统计最佳实践,用于评估和纠正非干预性研究中未测量混杂偏倚对因果治疗效果估计的潜在影响。
我们提出了一种用于评估未测量混杂的分层结构。首先,对于初始敏感性分析,我们强烈建议应用最近开发的方法,即 E 值,该方法易于应用,且不需要对未测量混杂因素(s)有任何先验知识或假设。当有一些这样的知识时,在这一步骤中,E 值可以通过排除或数组方法进行补充。如果这些初步分析表明结果可能对未测量混杂不稳健,则可以使用更专业的统计方法进行后续分析,我们根据这些方法是否需要访问可疑未测量混杂因素(s)的外部数据、内部数据或无数据对其进行分类。还介绍和讨论了选择后续敏感性分析方法的其他因素,包括未测量混杂的类型以及后续敏感性分析是否旨在提供校正后的因果治疗效果。
已经提出了各种分析方法来解决未测量的混杂问题,但很少有研究讨论在实践中选择适当方法的结构化方法。通过为选择适当的初始和潜在更专业的后续敏感性分析提供实用建议,我们希望促进非干预性研究中此类敏感性分析的广泛报告。所建议的方法还有可能在执行分析之前为敏感性分析提供预先指定,从而提高透明度并限制选择性研究报告。